BenRalizumab Effect on Airway Remodeling in Severe asTHma
Status:
RECRUITING
Trial end date:
2026-06-01
Target enrollment:
Participant gender:
Summary
Response to biologic therapies in severe asthma is variable, with patients being either non-responders, responders or super-responders. There is currently no explanation for this broad variation in response. It is important to examine whether these patients have distinct characteristics that could help the treating physician in making the correct diagnosis in clinical practice.
Aim of this clinical study is to evaluate the efficacy of benralizumab, a humanized an anti-interleukin 5 receptor α monoclonal antibody in patients with severe eosinophilic asthma and to evaluate airway remodeling before and after benralizumab treatment.
Hypothesis Identification of pathological and clinical characteristics in patients with severe eosinophilic asthma after benralizumab treatment regarding the airway remodeling, inflammatory cells, and other biomarkers on a long-term basis.
Research questions Is there any improvement in airway remodeling? Are there any biomarkers to predict response to benralizumab treatment in severe eosinophilic asthmatic patients?
Phase:
PHASE4
Details
Lead Sponsor:
Aristotle University Of Thessaloniki
Collaborators:
2nd Pulmonary Clinic, Kapodistrian University of Athens Pulmonary and Respiratory Failure Department, National and Kapodistrian University of Athens Pulmonary Clinic, Democritus University of Thrace Pulmonary Clinic, University of Ioannina University Hospital of Crete University Hospital of Patras